Emerging role of pemetrexed in ovarian cancer

References

• Jemal PA, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J. Clin.57(1), 43–66 (2007).
   PubMed Web of Science ®Google Scholar
• Bookman MA. Developmental chemotherapy and management of recurrent ovarian cancer. J. Clin. Oncol.21(Suppl.), 149s–167s (2003).
   PubMedGoogle Scholar
• Cannistra SA. Cancer of the ovary. N. Engl. J. Med.351, 2519–2529 (2004).
   PubMed Web of Science ®Google Scholar
• Armstrong D. Relapsed ovarian cancer: challenges and management strategies for a chronic disease. The Oncologist7, 20–28 (2007).
   Google Scholar
• Markman M, Hoskins W. Responses to salvage chemotherapy in ovarian cancer: a critical need for precise definitions of the treated population. J. Clin. Oncol.10, 513–514 (1992).
   PubMed Web of Science ®Google Scholar
• Ozols R. Systemic therapy for ovarian cancer: current status and new treatments. Semin. Oncol.33(Suppl.), S3–S11 (2006).
   Web of Science ®Google Scholar
• Salzberg M, Thurlimann B, Bonnefois H et al. Current concepts of treatment strategies in advanced or recurrent ovarian cancer. Oncology68, 293–298 (2005).
   PubMed Web of Science ®Google Scholar
• Martin LP, Schilder RJ. Management of recurrent ovarian carcinoma: current status and future directions. Semin. Oncol.36(2), 112–125 (2009).
   PubMed Web of Science ®Google Scholar
• Herzog TJ. The current treatment of recurrent ovarian cancer. Curr. Oncol. Rep.8, 448–454 (2006).
   PubMedGoogle Scholar
• Rose PG, Blessing JA, Mayer AR, Homesley HD. Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study. J. Clin. Oncol.16(2), 405–410 (1998).
   PubMed Web of Science ®Google Scholar
• Sehouli J, Stengel D, Oskay-Oezcelik G et al. Nonplatinum topotecan combinations versus topotecan alone for recurrent ovarian cancer: results of a Phase III study of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group. J. Clin. Oncol.26(19), 3176–3182 (2008).
   PubMed Web of Science ®Google Scholar
• Meier W, du Bois A, Reuss A et al. Topotecan versus treosulfan, an alkylating agent, in patients with epithelial ovarian cancer and relapse within 12 months following 1st-line platinum/paclitaxel chemotherapy. A prospectively randomized Phase III trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR). Gynecol. Oncol.114(2), 199–205 (2009).
   PubMed Web of Science ®Google Scholar
• Mutch DG, Orlando M, Goss T et al. Randomized Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J. Clin. Oncol.25(19), 2811–2818 (2007).
   PubMed Web of Science ®Google Scholar
• Ferrandina G, Ludovisi M, Lorusso D et al. Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. J. Clin. Oncol.26(6), 890–896 (2008).
   PubMed Web of Science ®Google Scholar
• Gordon AN, Tonda M, Sun S, Rackoff W; Doxil Study 30-49 Investigators. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a Phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol. Oncol.95(1), 1–8 (2004).
   PubMed Web of Science ®Google Scholar
• Piccart MJ, Green JA, Lacave AJ et al. Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: a randomized Phase II study of the European Organization for Research and Treatment of Cancer Gynecology Group. J. Clin. Oncol.18(6), 1193–1202 (2000).
   PubMed Web of Science ®Google Scholar
• ten Bokkel Huinink W, Lane SR, Ross GA; International Topotecan Study Group. Long-term survival in a Phase III, randomised study of topotecan versus paclitaxel in advanced epithelial ovarian carcinoma. Ann. Oncol.15(1), 100–103 (2004).
   PubMed Web of Science ®Google Scholar
• Pfisterer J, Plante M, Vergote I et al.; AGO-OVAR; NCIC CTG; EORTC GCG. J. Clin. Oncol.24(29), 4699–4707 (2006).
   PubMed Web of Science ®Google Scholar
• Parmar MK, Ledermann JA, Colombo N et al.; ICON and AGO Collaborators. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet361(9375), 2099–2106 (2003).
   PubMed Web of Science ®Google Scholar
• Rothenberg ML, Liu PY, Wilczynski S et al. Phase II trial of vinorelbine for relapsed ovarian cancer: a Southwest Oncology Group study. Gynecol. Oncol.95(3), 506–512 (2004).
   PubMed Web of Science ®Google Scholar
• Bajetta E, Di Leo A, Biganzoli L et al. Phase II study of vinorelbine in patients with pretreated advanced ovarian cancer: activity in platinum-resistant disease. J. Clin. Oncol.14(9), 2546–2551 (1996).
   PubMed Web of Science ®Google Scholar
• Krasner CN, McMeekin DS, Chan S et al. A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens. Br. J. Cancer97(12), 1618–1624 (2007).
   PubMed Web of Science ®Google Scholar
• Sessa C, De Braud F, Perotti A et al. Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails. J. Clin. Oncol.23(9), 1867–1874 (2005).
   PubMed Web of Science ®Google Scholar
• Rose PG, Fusco N, Fluellen L et al. Second-line therapy with paclitaxel and carboplatin for recurrent disease following first-line therapy with paclitaxel and platinum in ovarian or peritoneal carcinoma. J. Clin. Oncol.16, 1494–1497 (1998).
   PubMed Web of Science ®Google Scholar
• Bolis G, Scarfone G, Sciatta C et al. A Phase I/II study of topotecan in combination with carboplatin in recurrent epithelial ovarian cancer. Gynecol. Oncol.83, 477–480 (2001).
   PubMed Web of Science ®Google Scholar
• Pfisterer J, Vergote I, Du Bois A, Eisenhauer E; AGO-OVAR; NCIC CTG; EORTC GCG. Combination therapy with gemcitabine and carboplatin in recurrent ovarian cancer. Int. J. Gynecol. Cancer15(Suppl. 1), 36–41 (2005).
   PubMed Web of Science ®Google Scholar
• Muggia FM, Hainsworth JD, Jeffers S et al. Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J. Clin. Oncol.15, 3987–3993 (1997).
   Google Scholar
• Shih C, Chen VJ, Gosset LS et al. LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res.57, 1116–1123 (1997).
   PubMed Web of Science ®Google Scholar
• Adjei AA. Pemetrexed (ALIMTA), a novel multitargeted antineoplastic agent. Clin. Cancer Res.10, 4276s–4280s (2004).
   PubMed Web of Science ®Google Scholar
• Westerhof GR, Schornagel JH, Kathmann I et al. Carrier and receptor mediated transport of folate antagonists targeting folate-dependent enzymes: correlates of molecular structure and biological activity. Mol. Pharmacol.48, 459–471 (1995).
   PubMed Web of Science ®Google Scholar
• Manegold C, Gatzemeier U, von Pawel J et al. Front-line treatment of advanced non-small-cell lung cancer with MTA (LY231514, pemetrexed disodium, ALIMTA) and cisplatin: a multicenter Phase II trial. Ann. Oncol.11, 435–440, (2000).
   PubMed Web of Science ®Google Scholar
• Shepherd FA, Dancey J, Arnold A et al. Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group. Cancer92, 595–600 (2001).
   PubMed Web of Science ®Google Scholar
• Hanna N, Shepherd FA, Fossella FV et al. Randomized Phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J. Clin. Oncol.22, 1589–1597 (2004).
   PubMed Web of Science ®Google Scholar
• Paz-Ares L, Ciruelos E, Garcia-Carbonero R et al. Pemetrexed in bladder, head and neck, and cervical cancers. Semin. Oncol.29(Suppl. 18), 69–75 (2002).
   Google Scholar
• Wu M, Gunning W, Ratnam M. Expression of folate receptor type alpha in relation to cell type, malignancy, and differentiation in ovary, uterus, and cervix. Cancer Epidemiol. Biomarkers Prev.8, 775–782 (1999).
   PubMed Web of Science ®Google Scholar
• Garin A, Manikhas A, Biakhov M et al. A Phase II study of pemetrexed and carboplatin in patients with locally advanced or metastatic breast cancer. Breast Cancer Res. Treat.110, 309–315 (2008).
   PubMed Web of Science ®Google Scholar
• Scagliotti GV, Kortsik C, Dark GG et al. Pemetrexed combined with oxaliplatin or carboplatin as front-line treatment in advanced non-small cell lung cancer: a multicenter, randomized, Phase II trial. Clin. Cancer Res.11, 690–696 (2005).
   PubMed Web of Science ®Google Scholar
• Goedhals L, van Wiyk AL, Smith BL et al. Pemetrexed (Alimta, LY231514) demonstrates clinical activity in chemonaive patients with cervical cancer in a Phase II single-agent trial. Int. J. Gynecol. Cancer16, 1172–1178 (2006).
   PubMed Web of Science ®Google Scholar
• Miller DS, Blessing JA, Bodurka DC et al. Evaluation of pemetrexed (Alimta, LY231514) as second line chemotherapy in persistent or recurrent carcinoma of the cervix: a Phase II study of the Gynecologic Oncology Group. Gynecol. Oncol.110, 65–70 (2008).
   PubMed Web of Science ®Google Scholar
• Miller DS, Blessing JA, Krasner CN et al. Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a study of the Gynecologic Oncology Group. J. Clin. Oncol.27(16), 2686–2691 (2009).
   PubMed Web of Science ®Google Scholar
• Vergote I, Calvert H, Kania M, Kaiser C, Zimmermann AH, Sehouli J. A randomised, double-blind, phase II study of two doses of pemetrexed in the treatment of platinum-resistant, epithelial ovarian or primary peritoneal cancer. Eur. J. Cancer45(8), 1415–1423 (2009).
   PubMed Web of Science ®Google Scholar
• Gasent Blesa JM, Alberola Candel V, Provencio Pulla M, Esteban González E, Martín Algarra S. Management of platinum-resistant ovarian cancer with the combination of pemetrexed and gemcitabine. Clin. Transl. Oncol.11(1), 35–40 (2009).
   PubMed Web of Science ®Google Scholar
• Matulonis UA, Horowitz NS, Campos SM et al. Phase II study of carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer. J. Clin. Oncol.26(35), 5761–5766 (2008).
   PubMed Web of Science ®Google Scholar
• Rinaldi DA, Burris HA, Dorr FA et al. Initial Phase I evaluation of the novel thymidylate synthase inhibitor, LY231514, using the modified continual reassessment method for dose escalation. J. Clin. Oncol.13, 2842–2850 (1995).
   PubMed Web of Science ®Google Scholar
• McDonald AC, Vasey PA, Adams L et al. A Phase I and pharmacokinetic study of LY231514, the multitargeted antifolate. Clin. Cancer Res.4, 605–610 (1998).
   PubMed Web of Science ®Google Scholar
• Rinaldi DA. Overview of phase I trials of multitargeted antifolate (MTA, LY231514). Semin. Oncol.26(2 Suppl. 6), 82–88 (1999).
   PubMed Web of Science ®Google Scholar
• Rusthoven JJ, Eisenhauer E, Butts C et al. Multitargeted antifolate, LY231514, as first-line chemotherapy for patients with advanced non-small-cell lung cancer: a Phase II study – National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol.17, 1194–1199 (1999).
   PubMed Web of Science ®Google Scholar
• Sharma A, Johnson RD, Woodworth JM. Comparative human pharmacokinetics of MTA in three Phase I studies. Proc. Am. Soc. Clin. Oncol.17, 235a (1998) (Abstract 900).
   Google Scholar
• Allen RH, Stabler SP, Savage DG, Lindenbaum J. Metabolic abnormalities in cobalamin (vitamin B12) and folate deficiency. FASEB J. Rev.7, 1344–1353 (1993).
   PubMed Web of Science ®Google Scholar
• Niyikiza C, Baker SD, Seitz DE et al. Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy. Mol. Cancer Ther.1, 545–552 (2002).
   PubMed Web of Science ®Google Scholar
• Vogelzang NJ, Rusthoven JJ, Symanowski J et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J. Clin. Oncol.21(14), 2636–2644 (2003).
   PubMed Web of Science ®Google Scholar
• Rinaldi DA, Kuhn JG, Burris HA et al. A Phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation. Cancer Chemother. Pharmacol.44, 372–380 (1999).
   PubMed Web of Science ®Google Scholar
• Frenia ML, Long KS. Methotrexate and nonsteroidal anti-inflammatory drug interactions. Ann. Pharmacother.26, 234–237 (1992).
   PubMed Web of Science ®Google Scholar
• Sweeney CJ, Takimoto CH, Latz JE et al. Two drug interaction studies evaluating the pharmacokinetics and toxicity of pemetrexed when coadministered with aspirin or ibuprofen in patients with advanced cancer. Clin. Cancer Res.12, 536–542 (2006).
   PubMed Web of Science ®Google Scholar
• Thodtmann R, Depenbrock H, Dumez H et al. Clinical and pharmacokinetic Phase I study of multitargeted antifolate (LY231514) in combination with cisplatin. J. Clin. Oncol.17, 3009–3016 (1999).
   PubMed Web of Science ®Google Scholar
• Smith G, Amyx H, Boytos CM et al. Enhanced antitumor activity for the thymidylate synthase inhibitor 1843U89 through decreased host toxicity with oral folic acid. Cancer Res.55, 6117–6125 (1995).
   Google Scholar
• Alati T, Worzalla JF, Shih C et al. Augmentation of the therapeutic activity of lometrexol – (6-R)5,10-dideazatetrahydrofolate – by oral folic acid. Cancer Res.56, 2331–2335 (1996).
   PubMed Web of Science ®Google Scholar
• Bunn P, Paoletti P, Niyikiza C et al. Vitamin B12 and folate reduce toxicity of Alimta (pemetrexed disodium, LY231514, MTA), a novel antifolate/antimetabolite. Proc. Am. Soc. Clin. Oncol.20, (2001) (Abstract 300).
   Google Scholar
• Kaye SB. Chemotherapy for ovarian cancer: future potential for new and existing drugs. Am. Soc. Clin. Oncol. Ed. Book411–415 (2005).
   Google Scholar
• Kano Y, Akutsu M, Tsunoda S et al. Schedule-dependent interactions between pemetrexed and cisplatin in human carcinoma cell lines in vitro. Oncol. Res.16, 85–95 (2006).
   PubMed Web of Science ®Google Scholar
• Tomassetti A, Mangiarotti F, Mazzi M et al. The variant hepatocyte nuclear factor 1 activates the P1 promoter of the human α-folate receptor gene in ovarian carcinoma. Cancer Res.63, 696–704 (2003).
   Google Scholar
• Hsu DS, Balakumaran BS, Acharya CR et al. Pharmacogenomic strategies provide a rational approach to the treatment of cisplatin-resistant patients with advanced cancer. J. Clin. Oncol.25(28), 4350–4357 (2007).
   PubMed Web of Science ®Google Scholar
• Gordon AN, Fleagle JT, Guthrie D et al. Recurrent epithelial ovarian carcinoma: A randomized Phase III study of pegylated liposomal doxorubicin versus topotecan. J. Clin. Oncol.19, 3312–3322 (2001).
   PubMed Web of Science ®Google Scholar
• Lund B, Hansen OP, Theilade K et al. Phase II study of gemcitabine in previously treated ovarian cancer patients. J. Natl Cancer Inst.86, 1530–1533 (1994).
   PubMed Web of Science ®Google Scholar
• Shapiro JD, Millward MJ, Rischin D et al. Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel. Gynecol. Oncol.63, 89–93 (1996).
   PubMed Web of Science ®Google Scholar
• Tonkinson JL, Worzalla JF, Teng CH, Mendelsohn LG. Cell cycle modulation by a multitargeted antifolate, LY231514, increases the cytotoxicity and antitumor activity of gemcitabine in HT29 colon carcinoma. Cancer Res.59, 3671–3676 (1999).
   PubMed Web of Science ®Google Scholar
• Giovannetti E, Mey V, Danesi R, Mosca I, Del Tacca M. Synergistic cytotoxicity and pharmacogenetics of gemcitabine and pemetrexed combination in pancreatic cancer cell lines. Clin. Cancer Res.10, 2936–2943 (2004).
   PubMed Web of Science ®Google Scholar
• Giovannetti E, Mey V, Nannizzi S et al. Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human non-small-cell lung cancer cells. Mol. Pharmacol.68, 110–118 (2005).
   PubMed Web of Science ®Google Scholar
• Chen VJ, Bewley JR, Andis SL et al. Preclinical cellular pharmacology of LY231514 (MTA): a comparison with methotrexate, LY309887 and raltitrexed for their effects on intracellular folate and nucleoside triphosphate pools in CCRF-CEM cells. Br. J. Cancer78(Suppl. 3), 27–34 (1998).
   PubMedGoogle Scholar
• Ma CX, Nair S, Thomas S et al. Randomized Phase II trial of three schedules of pemetrexed and gemcitabine as front-line therapy for advanced non-small-cell lung cancer. J. Clin. Oncol.23, 5929–5937 (2005).
   PubMed Web of Science ®Google Scholar
• Abulafia O, Triest WE, Sherer DM. Angiogenesis in primary and metastatic epithelial ovarian carcinoma. Am. J. Obstet. Gynecol.177, 541–547 (1997).
   PubMedGoogle Scholar
• Alvarez AA, Krigman HR, Whitaker RS et al. The prognostic significance of angiogenesis in epithelial ovarian carcinoma. Clin. Cancer Res.5, 587–591 (1999).
   PubMed Web of Science ®Google Scholar
• Goodheart MJ, Ritchie JM, Rose SL et al. The relationship of molecular markers of p53 function and angiogenesis to prognosis of stage I epithelial ovarian cancer. Clin. Cancer Res.11, 3733–3742 (2005).
   PubMed Web of Science ®Google Scholar
• Paley PJ, Staskus KA, Gebhard K et al. Vascular endothelial growth factor expression in early stage ovarian carcinoma. Cancer80, 98–106 (1997).
   PubMed Web of Science ®Google Scholar
• Garcia AA, Oza AM, Hirte HW et al. Interim report of a Phase II clinical trial of bevacizumab (Bev) and low dose metronomic oral cyclophosphamide (mCTX) in recurrent ovarian (OC) and primary peritoneal carcinoma: a California Cancer Consortium Trial. J. Clin. Oncol.23(Suppl.), 455s, (2005) (Abstract 5000).
   PubMed Web of Science ®Google Scholar
• Cohn DE, Valmadre S, Resnick KE et al. Bevacizumab and weekly taxane chemotherapy demonstrates activity in refractory ovarian cancer. Gynecol. Oncol.102, 134–139 (2006).
   PubMed Web of Science ®Google Scholar
• Monk BJ, Han E, Josephs-Cowan CA et al. Salvage bevacizumab (rhuMAB VEGF)-based therapy after multiple prior cytotoxic regimens in advanced refractory epithelial ovarian cancer. Gynecol. Oncol.102, 140–144 (2006).
   PubMed Web of Science ®Google Scholar
• Wright JD, Hagemann A, Rader JS et al. Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma: a retrospective analysis. Cancer107, 83–89 (2006).
   PubMed Web of Science ®Google Scholar
• Burger RA, Sill M, Monk BJ et al. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer (EOC) or primary peritoneal cancer (PPC): a Gynecologic Oncology Group (GOG) study. J. Clin. Oncol.23(Suppl.), 457s, (2005) (Abstract 5009).
   Google Scholar
• Cannistra SA, Matulonis U, Penson R et al. Bevacizumab in patients with advanced platinum-resistant ovarian cancer. J. Clin. Oncol.24(Suppl.), 257s, (2006) (Abstract).
   Google Scholar
• Weiss GJ, Zeng C, Kelly K et al. Single institution experience with pemetrexed and bevacizumab as salvage therapy in advanced non-small-cell lung cancer. Clin. Lung Cancer8, 335–338 (2007).
   Google Scholar
• Herbst RS, O’Neill VJ, Fehrenbacher L et al. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer. J. Clin. Oncol.25, 4743–4750 (2007).
   PubMed Web of Science ®Google Scholar
• Patel JD, Hensing TA, Rademaker A et al. Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer. J. Clin. Oncol.27(20), 3284–3289 (2009).
   PubMed Web of Science ®Google Scholar